Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.

Reuters • 17 hours ago

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that infants immunized against RSV in their first season had fewer RSV hospitalizations in their second season The study also showed a reduction of 85.9% in RSV-related lower respiratory tract infection hospitalizations in the first season Data published in The Lancet Infectious Diseases and to be presented at RSVVW '26 conference in Rome Paris, February 16, 2026. A universal respiratory syncytial virus (RSV) immunization program using Beyfortus (nirsevimab) was associated with a statistically significant reduction in RSV-related hospitalizations in the second RSV season among infants immunized during their first season, according to a new study published in  The Lancet Infectious Diseases.

GlobeNewsWire • a day ago

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major task to win over investors, accelerate the French company's stalled drug development pipeline and navigate vaccine scepticism in the United States under President Donald Trump.

Reuters • Feb 13, 2026

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi SA (NASDAQ: SNY) shares are down during Friday's premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.

Benzinga • Feb 13, 2026

SNY Stock Falls After Board Suddenly Makes Leadership Change

Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudson's mandate and names Belen Garijo as successor amid investor skepticism.

Zacks Investment Research • Feb 13, 2026

Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate

French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.

Reuters • Feb 12, 2026

Who is Sanofi's new CEO Belén Garijo?

French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.

Reuters • Feb 12, 2026

Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson

Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO, replacing him with Merck KGaA's Belen Garijo.

Investors Business Daily • Feb 12, 2026

Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO

Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.

WSJ • Feb 12, 2026

Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued

Sanofi reported FY net sales up >9% to €43.6bn and net income up >12% to €9.5mn. Despite strong results, Sanofi announced today it has replaced CEO Paul Hudson with former employee Belén Garijo, signaling urgency for improved execution and R&D innovation. Sanofi remains heavily reliant on Dupixent, which generated ~€15.7bn, or 36% of total 2024 revenues.

Seeking Alpha • Feb 12, 2026